Search Results
Apr 20, 2026, 13:15 ET Verismo Therapeutics' Initial Clinical Data from STAR-101 Phase 1 Trial of SynKIR™-110 KIR-CAR Presented at AACR 2026 Plenary Session
dose level cohorts 1 through 3 showed a favorable safety profile, with no dose-limiting toxicities, no high-grade (Gr3+) cytokine release syndrome (CRS), and no immune effector cell-associated neurotoxicity syndrome (ICANS) events observed.The initial data showed on-target biologic activity based
More news about: Verismo Therapeutics
Apr 20, 2026, 10:00 ET AACR 2026 Oral Presentation: Abogen Presents Preliminary Results of ABO2203 (mRNA-Encoded CD3×CD19 TCE) from First-in-Human Clinical Study in R/R B-NHL
ABO2203 is designed to mitigate cytokine release syndrome (CRS) while maintaining robust clinical efficacy.The Key to TCE Therapies: Overcoming CRS ToxicityNearly all marketed protein-based TCEs carry black-box warnings for CRS, which remains a primary safety challenge in the development
More news about: Abogen
Apr 20, 2026, 10:00 ET AACR 2026 Oral Presentation: Abogen Presents Preliminary Results of ABO2203 (mRNA-Encoded CD3×CD19 TCE) from First-in-Human Clinical Study in R/R B-NHL
ABO2203 is designed to mitigate cytokine release syndrome (CRS) while maintaining robust clinical efficacy.The Key to TCE Therapies: Overcoming CRS ToxicityNearly all marketed protein-based TCEs carry black-box warnings for CRS, which remains a primary safety challenge in the development
More news about: Abogen
Apr 17, 2026, 20:30 ET Antengene Presents Three Novel Programs at AACR 2026, Highlighting Next-Generation ADC and AnTenGager® TCEs
developed ATG-106, a novel "2+1", sterically masked CDH6 x CD3 bispecific TCE designed to deliver potent antitumor activity with the potential for a reduced CRS risk profile.Results: ATG-106 exhibited reduced binding affinity to CD3+ cells before CDH6 crosslinking, while inducing approximately
More news about: Antengene Corporation Limited
Apr 13, 2026, 15:00 ET BioOra and Cincinnati Children's Hospital Medical Center Partner to Advance Next-Generation CAR-T Therapy for Children with Leukaemia
and limited treatment options. First-generation approved CAR-T therapies have demonstrated meaningful efficacy. However, cytokine release syndrome (CRS) and, in particular, immune effector cell-associated neurotoxicity syndrome (ICANS), remain barriers to broader adoption, especially in paediatric patients,
More news about: BioOra
Apr 09, 2026, 07:00 ET VSBLTY ANNOUNCES CONTRACT AWARD AND INITIAL DEPLOYMENT OF MULTI-SENSOR GOVERNED INTELLIGENCE PLATFORM FOR DEFENSE EARLY-WARNING, COUNTER DRONE, AND CRITICAL INFRASTRUCTURE PROTECTION
accountability from AI systems, governed intelligence is not optional -- it is the standard. Working with CRS as the systems integrator, we are demonstrating that standard in the field."Mr. Kazi, CEO of CRS Inc. added:"VSBLTY's software platform provides a critical component of the digital
More news about: VSBLTY
Apr 07, 2026, 09:27 ET Live Cell Observation System Selected for NASA-Supported Project Heading to the International Space Station
manager of the ISS National Laboratory. The U.S. National Aeronautics and Space Administration's (NASA) Northrop Grumman Commercial Resupply Services (CRS) 24 mission is set to launch to the space station from Cape Canaveral Space Force Station, Florida in early April 2026. On this mission, foundational
More news about: Nikon Instruments Inc.
Mar 31, 2026, 09:07 ET Dominari 2025 Revenue Surges 487% in 2025, Balance Sheet Strengthens Significantly
the principal invested. You can check the background of Dominari Securities LLC and its registered investment professionals and review its SEC Form CRS on FINRA's BrokerCheck site at
More news about: Dominari Holdings Inc.
Mar 30, 2026, 09:53 ET Harbour BioMed Reports Full Year 2025 Financial Results: Sustained Global Collaboration Underpins Long-Term Growth
activation and cell elimination. By incorporating dual anti-BCMA binding sites for optimal cell targeting and monovalent-optimized CD3 activity to minimize CRS, HBM7020 demonstrated potent cytotoxicity with broad applications in both immunological and oncology diseases. In August 2023, HBM7020 obtained IND clearance
More news about: Harbour BioMed
Mar 26, 2026, 09:54 ET Keymed Biosciences Announces 2025 Annual Results and Business Updates
multiple myeloma (RRMM). As of July 2025, in the Phase II dose-expansion stage, only 4.7% of subjects experienced Grade 2 cytokine release syndrome (CRS) events, with no immune effector cell-associated neurotoxicity syndrome (ICANS) events occurring. The objective response rate (ORR) in the target dose
More news about: Keymed
Mar 20, 2026, 05:06 ET Antengene Announces 2025 Full-Year Results: First TCE Out-licensing Validates Platform Value and Marks Inflection Point Towards 2026 Profitability
for low-expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform's broad applicability across autoimmune diseases, solid tumors and hematological
More news about: Antengene Corporation Limited
Mar 19, 2026, 09:44 ET CytoSorbents Announces HotSwap™ Launch, Renewed Aferetica Partnership, and New Clinical Evidence at ISICEM 2026
rightDr. Gabriella Bottari, Rome/ItalyThe new kid on the block – Cytokine Release Syndrome (CRS) after CAR-T cell therapyDr. Peter Pickkers, Nijmegen/The NetherlandsIn addition, multiple abstracts and poster
More news about: Cytosorbents Corp
Mar 18, 2026, 07:01 ET Kali Therapeutics Announces First Patient Dosed in Phase 1a Clinical Trial of KT501 for Rheumatoid Arthritis
traditional B-cell therapies, KT501 is designed to maximize B-cell killing potency while significantly reducing the risk of cytokine release syndrome (CRS), a common hurdle for T-cell engaging therapies."We are deeply grateful to the patients, lead Principal Investigator Prof. Stephen Hall, and the
More news about: Kali Therapeutics
Mar 18, 2026, 06:20 ET Bengaluru-based TerraTern Emerges As a Global Hub for AI-Powered Immigration, Work & Study Abroad Guidance
programs. For Canada, they optimise Express Entry CRS scores and Provincial Nominee Programs.
More news about: TerraTern
Mar 17, 2026, 20:30 ET Antengene to Present on Three Preclinical Programs at AACR 2026, Highlighting Next-Generation ADCs and AnTenGager™ TCEs
for low expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform's broad applicability across autoimmune disease, solid tumors and hematological malignancies,
More news about: Antengene Corporation Limited
Mar 17, 2026, 05:00 ET Korean Air deploys IBS Software's iFlight Platform to transform Flight Operations and Crew Management
management. Across the hospitality sector, IBS Software offers a cloud-native, unified platform for hotels and travel sellers, including central reservation (CRS), property management (PMS), revenue management (RMS), call centre, booking engine, loyalty, and distribution. For the tour & cruise industry, IBS
More news about: IBS Software
Mar 16, 2026, 08:00 ET Dominari Releases Letter to Shareholders and Clients
all of the principal invested. You can check the background of Dominari Securities and its registered investment professionals and review its SEC Form CRS on FINRA's BrokerCheck site at
More news about: Dominari Holdings Inc.
Mar 16, 2026, 08:00 ET Celltrion announces U.S. availability of AVTOZMA® (tocilizumab-anoh) subcutaneous (SC) formulation
July 2025, the FDA approved an additional indication for the intravenous (IV) formulation of AVTOZMA for the treatment of cytokine release syndrome (CRS) in adult and pediatric patients aged two years and older.INDICATION AVTOZMA® (tocilizumab-anoh) IV is an interleukin-6
More news about: Celltrion
Mar 10, 2026, 08:31 ET Ledgible and Label Partner to Streamline Digital Asset Tax Information CARF & DAC8 Reporting and Compliance
Label is a leading provider of automated end-to-end compliance software and expert tax services, specializing in FATCA, CRS, and CARF due diligence and reporting solutions. With a team combining regulatory expertise from top financial institutions and advanced engineering
More news about: Ledgible
Mar 05, 2026, 17:31 ET Chronic Rhinosinusitis with Nasal Polyps Market Shows Strong Upward Momentum During the Forecast Period (2026-2036) as Demand for Advanced Therapies Rises | DelveInsight
epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:Prevalent Cases of CRSDiagnosed Prevalent Cases of CRSDiagnosed Prevalent Cases of CRSwNPGender-specific Diagnosed Prevalent Cases of CRSwNPTotal Treated Cases
More news about: DelveInsight Business Research, LLP
Mar 05, 2026, 15:55 ET Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line
SYNDROMECytokine release syndrome (CRS), including life-threatening or fatal reactions, can occur in patients receiving TECVAYLI. Initiate treatment with TECVAYLI step-up dosing schedule to reduce risk of CRS. Withhold TECVAYLI until CRS resolves or permanently discontinue based on severity.Neurologic
More news about: Johnson & Johnson
Mar 04, 2026, 09:15 ET Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma
fever, and transient liver enzyme elevations; Grade 3 cytopenias were consistent with expected lymphodepletion. CAR-T related cytokine release syndrome (CRS) occurred in 43% of patients (all Grade 1/2), and immune effector cell‑associated neurotoxicity syndrome (ICANS) occurred in 21% (primarily low grade)."In
More news about: Citius Oncology, Inc.
Mar 03, 2026, 17:00 ET Antengene and UCB Enter Global License Agreement for ATG-201, a CD19/CD3 Bispecific T-Cell Engager for Autoimmune Diseases
technology and proprietary CD3 sequence, a strategy designed to enable effective B cell depletion and reduce the risk of cytokine release syndrome (CRS). This collaboration further underscores AnTenGager™ platform's unique capability in developing next generation novel TCEs with broad applicability
More news about: Antengene Corporation Limited
Mar 03, 2026, 17:00 ET Antengene and UCB Enter Global License Agreement for ATG-201, a CD19/CD3 Bispecific T-Cell Engager for Autoimmune Diseases
technology and proprietary CD3 sequence, a strategy designed to enable effective B cell depletion and reduce the risk of cytokine release syndrome (CRS). This collaboration further underscores AnTenGager™ platform's unique capability in developing next generation novel TCEs with broad applicability
More news about: Antengene Corporation Limited
Mar 03, 2026, 01:00 ET Aven Hospitality Announces MCP Enablement Across Its Platform, Strengthening Hotels' Position in AI-Driven Discovery
SynXis Central Reservation System (CRS) and
More news about: Aven Hospitality